Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy. — Sofia Karageorgopoulou (2017) | RDL Network
Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
Article 2017 en
Authors
SK
Sofia Karageorgopoulou
IK
Ioannis D. Kostakis
MG
Maria Gazouli
Abstract
1 min read
ERCC1 expression proved to be a significant prognostic factor for survival in our metastatic or recurrent cervical cancer population treated with cisplatin based chemotherapy. ERCC1 N118 N and MDR1 G2677 T polymorphism also proved of prognostic significance for disease progression, while overexpression of III β-tubulin was positively correlated with chemotherapy resistance.
A. Bamias, Nikitas Nikitas, Alexandra Karadimou, Dimitra Gika, Vasilios Karavasilis, Evangelos Briasoulis, Michael Chrisofos, Sara E. Murray, D. Pectasides, Meletios A Dimopoulos
Aristotelis Bamias, Efstathios Kastritis, George Bozas, Vassiliki Koutsoukou, N. Antoniou, H. Katsifotis, K. Konstantinidis, Andreas Skolarikos, C. Deliveliotis, Meletios A Dimopoulos
Discussion(0)
No comments yet. Be the first to comment.